Meeting
2013 ASCO Annual Meeting
Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC).
Authors
Benjamin J. Solomon
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
Benjamin J. Solomon , Scott N. Gettinger , Gregory J. Riely , Shirish M. Gadgeel , Hiroshi Nokihara , Ji-Youn Han , Toyoaki Hida , Miyako Satouchi , Editta Baldini , Salvatore Siena , Nobuyuki Yamamoto , Leora Horn , Vanessa Roberts Tassell , Anna Polli , D. Ross Camidge
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT00932893
Citation
J Clin Oncol 31, 2013 (suppl; abstr 8105)
DOI
10.1200/jco.2013.31.15_suppl.8105
Abstract #
8105
Poster Bd #
40E
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)
First Author: Tony Mok
Poster
2013 ASCO Annual Meeting
Impact of crizotinib on patient-reported symptoms and quality of life (QOL) compared with single-agent chemotherapy in a phase III study of advanced ALK+ non-small cell lung cancer (NSCLC).
First Author: Vera Hirsh
Poster
2016 ASCO Annual Meeting
Phase 3 study of first-line crizotinib vs pemetrexed−cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).
First Author: Shun Lu
First Author: Cesare Gridelli